Abstracts tagged "Economics"

Abstract Number: 386 • 2012 ACR/ARHP Annual Meeting
Costs of Tumor Necrosis Factor Blockers Per Treated Rheumatoid Arthritis Patient Using Real-World Drug Data in a US Managed Care Population
Vernon F. Schabert¹, Crystal Watson², George Joseph², Paige Iversen¹, Chakkarin Burudpakdee¹ and David J. Harrison², ¹IMS Health, Alexandria, VA, ²Amgen Inc., Thousand Oaks, CA
Background/Purpose: Etanercept (ETN), adalimumab (ADA), and infliximab (INF) are FDA-approved tumor necrosis factor (TNF)-blocker treatments for moderate to severe rheumatoid arthritis (RA) and are commonly…
Abstract Number: 270 • 2012 ACR/ARHP Annual Meeting
Use of Drug Combinations in Patients with Osteoarthritis: A Population-Based Cohort Study
Daniel Prieto-Alhambra¹ and Rosa Morros², ¹Internal Medicine; Primary Care; NDORMS Dept; MRC Lifecourse Epidemiology Unit, URFOA-IMIM, Parc de Salut Mar; Idiap Jordi Gol; University of Oxford; University of Southampton, Barcelona, Spain, ²Primary Care, IDIAP Jordi Gol; Institut Català de la Salut, Spain
TITLE: "Use of drug combinations in patients with osteoarthritis: a population-based cohort study."Background/Purpose: Patients affected with osteoarthritis (OA) use different drugs in search for relief.…
Abstract Number: 60 • 2012 ACR/ARHP Annual Meeting
The Burden of Early Arthritis in Latin America: Utility Analysis Using Patient-Level Data From the Argentinian Consortium for Early Arthritis
Christian A. Waimann¹, Gustavo Citera², Hernan Maldonado Ficco³, Oscar L. Rillo⁴, Mariana Benegas⁵, Rafael Chaparro del Moral⁶, Antonio Catalan Pellet⁷, Anastasia Secco⁸, Lucila Marino⁹, Alberto Berman¹⁰, Horacio Berman¹⁰, Ana Lucía Barbaglia¹¹, Juan Carlos Marcos¹², Josefina Marcos¹³, Francisco Caeiro¹⁴, Maria Haye Salinas¹⁵, Ana C. Alvarez¹⁶, Enrique Soriano¹⁷, Zaida Bedran¹⁸, Sergio Paira¹⁹, Federico Ceccato¹⁹, Gabriela Salvatierra²⁰, Ana Quinteros²¹, Emilio Buschiazzo²² and Edson Javier Velozo²³, ¹Rheumatology section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Instituto de Rehabilitacion Psicofisica, Buenos Aires, Argentina, ⁴Rheumatology, Hospital General de Agudos "Dr. E. Tornú", Buenos Aires, Argentina, ⁵Rheumatology, Hospital Tornu, Buenos Aires, Argentina, ⁶Rheumatology Section, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ⁷Rheumatology, Hospital Rivadavia, Buenos Aires, Argentina, ⁸Rheumathology, Hospital Bernardino Rivadavia, Buenos aires, Argentina, ⁹Rheumathology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ¹⁰Centro Medico Privado de Reumatologia, Tucuman, Argentina, ¹¹Rheumatology, Hospital Padilla, Tucuman, Argentina, ¹²Rheumatology, Hospital San Martin, La Plata, Argentina, ¹³Rheumatology Unit, HIGA San Martín La Plata, La Plata, Argentina, ¹⁴Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ¹⁵Reumatología, Hospital Privado de Córdoba, Córdoba, Argentina, ¹⁶Rheumatology, Hospital Privado, Córdoba, Argentina, ¹⁷Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹⁸Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹⁹Rheumatology, Hospital Jose Maria Cullen, Santa Fe, Argentina, ²⁰Rheumatology, Centro de enfermedades Reumaticas, Santiago Del Estero, Argentina, ²¹Centro Integral de Reumatología, Tucumán, Argentina, ²²Rheumatology, Hospital Señor del Milagro, Salta, Argentina, ²³Rheumatology, Sanatorio Adventista del Plata, Entre Rios, Argentina
Background/Purpose: Rheumatoid arthritis (RA) is estimated to be one of the leading causes of non-fatal burden in the world. However, data from developing countries including…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].